title: Improved orthostatic tolerance in familial amyloidotic polyneuropathy with unnatural noradrenaline precursor L-threo-3,4-dihydroxyphenylserine.
abstract: Disabling orthostatic hypotension, due to insufficiency of the autonomic nervous system, is a common complication of type I familial amyloidotic polyneuropathy (FAP). We investigated whether oral treatment with L-threo-3,4-dihydroxyphenylserine (L-threo-Dops), a noradrenaline precursor, might be of therapeutical benefit. In twenty untreated FAP patients, aged 33 to 44 years, who, because of severe orthostatic hypotension, were bedridden or constrained to a sitting life, supine and erect blood pressure (BP), plasma noradrenaline and tilting time, defined as the interval (s) between the beginning of a 60 degrees head-up tilt and the occurrence of orthostatic symptoms (dizziness, blurred vision or near syncope) were determined before and at repeated intervals during oral treatment with L-threo-Dops, 100 mg bid, for 6 months. Before treatment supine mean BP was 80 (76-85) mmHg (mean and 95% CI), supine plasma noradrenaline was low, 59 (41-77) pg/ml and tilting time ranged from 38 to 118 s. In response to tilt, mean BP immediately fell by 36 (31-41) mmHg, whereas plasma noradrenaline increased by only 11 (0-21) pg/ml (p = 0.05). After 3 to 5 days of treatment with L-threo-Dops all patients experienced marked improvement of their orthostatic tolerance as reflected by their ability to walk freely around. This effect sustained throughout the six months of treatment. Plasma noradrenaline increased moderately by 37 (11-63) pg/ml (p = 0.02) and supine mean BP increased by 8.6 (5.8-12.4) mmHg (p < 0.001) during chronic treatment. Supine or nocturnal hypertension did not develop, the fall in mean BP in response to tilt diminished by 12.5 (6.5-17.3) mmHg (p < 0.001) and tilting time became longer than 600 s in all patients. Because of its efficacy, its sustained duration of action and the lack of side effects, L-threo-Dops is advocated to improve orthostatic tolerance in patients with autonomic insufficiency due to FAP.
authors.affiliation: Centro de Estudos de Funçao Autonomica Hospital S. Joao, Oporto, Portugal.
authors.forename: M J
authors.initials: MJ
authors.lastname: Carvalho
authors.forename: A H
authors.initials: AH
authors.lastname: van den Meiracker
authors.forename: F
authors.initials: F
authors.lastname: Boomsma
authors.forename: A J
authors.initials: AJ
authors.lastname: Man in 't Veld
authors.forename: J
authors.initials: J
authors.lastname: Freitas
authors.forename: O
authors.initials: O
authors.lastname: Costa
authors.forename: A F
authors.initials: AF
authors.lastname: de Freitas
mesh_terms: D000328:Adult; D017772:Amyloid Neuropathies / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D015103:Droxidopa / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007024:Hypotension, Orthostatic / Q000188:drug therapy*; D008297:Male; D009638:Norepinephrine / Q000378:metabolism
chemical_list: D015103:Droxidopa; D009638:Norepinephrine